Ethnic comparisons of antipsychotic use in schizophrenia

Australian and New Zealand Journal of Psychiatry

Volumn 42, Issue 10, 2008, Pages 863-873

  Wheeler, Amanda ^a,b   Humberstone, Verity ^c   Robinson, Elizabeth ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Waitakere Hospital   (New Zealand)

^c Division of Medicine Emergency and Integrated Care   (New Zealand)

Author keywords

Antipsychotic; Community; Ethnicity; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ASIAN; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG USE; ETHNIC DIFFERENCE; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAORI; MONOTHERAPY; NEW ZEALAND; PACIFIC ISLANDS; POLYPHARMACY; PRESCRIPTION; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CATCHMENT AREA (HEALTH); CHLORPROMAZINE; CLOZAPINE; CROSS-CULTURAL COMPARISON; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; DRUG THERAPY; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; SCHIZOPHRENIA; YOUNG ADULT;

EID: 51649093324     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670802345482     Document Type: Article

References (75)

1. Snowden, LR and Cheung, FK. (1990) Use of inpatient mental health services by members of ethnic minority groups. Am Psychol, 45, pp. 347-355.
2. Adebimpe, VR. (1994) Race, racism, and epidemiological surveys. Hosp Community Psychiatry, 45, pp. 27-31.
3. Lawson, WB, Hepler, N., Holladay, J. and Cuffel, B. (1994) Race as a factor in inpatient and outpatient admissions and diagnosis. Hosp Community Psychiatry, 45, pp. 72-74.
4. Bhui, K., Stansfeld, S., Hull, S., Priebe, S., Mole, F. and Feder, G. (2003) Ethnic variations in pathways to and use of specialist mental health services in the UK. Systematic review. Br J Psychiatry, 182, pp. 105-116.
5. Singh, SP, Greenwood, NAN, White, S. and Churchill, R. (2007) Ethnicity and the Mental Health Act 1983. Br J Psychiatry, 191, pp. 99-105.
6. Blanco, C., Patel, SR Liu, L. et al. (2007) National trends in ethnic disparities in mental health care. Med Care, 45, pp. 1012-1019.
7. Price, N., Glazer, W. and Morgenstern, H. (1985) Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. Am J Psychiatry, 142, pp. 1491-1492.
8. Lloyd, K. and Moodley, P. (1992) Psychotropic medication and ethnicity: an inpatient survey. Soc Psychiatry Psychiatr Epidemiol, 27, pp. 95-101.
9. Segal, SP, Bola, JR and Watson, MA. (1996) Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv, 47, pp. 282-286.
10. Citrome, L., Levine, J. and Allingham, B. (1996) Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull, 32, pp. 321-326.
11. Lehman, AF and Steinwachs, DM. (1998) Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophr Bull, 24, pp. 11-20.
12. Walkup, JT, McAlpine, DD, Olfson, M., Labay, LE, Boyer, C. and Hansell, S. (2000) Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry, 61, pp. 344-348.
13. Diaz, FJ and De Leon, J. (2002) Excessive antipsychotic dosing in 2 U.S. State hospitals. J Clin Psychiatry, 63, pp. 998-1003.
14. Wang, PS, West, JC, Tanielian, T. and Pincus, HA. (2000) Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull, 26, pp. 451-457.
15. Owen, RR, Feng, W., Thrush, CR, Hudson, TJ and Austen, MA. (2001) Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs hospitals. Psychiatr Serv, 52, pp. 1523-1525.
16. Covell, NH, Jackson, CT, Evans, AC and Essock, SM. (2002) Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull, 28, pp. 17-29.
17. Kuno, E. and Rothbard, AB. (2002) Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry, 159, pp. 567-572.
18. Mark, T., Dirani, R., Slade, E. and Russo, P. (2002) Access to new medications to treat schizophrenia. J Behav Health Serv Res, 29, pp. 15-29.
19. Kreyenbuhl, J., Zito, JM, Buchanan, RW, Soeken, KL and Lehman, AF. (2003) Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull, 29, pp. 183-194.
20. Opolka, JL, Rascati, KL, Brown, CM and Gibson, PJ. (2004) Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv, 55, pp. 151-156.
21. Copeland, LA, Zeber, JE, Valenstein, M. and Blow, FC. (2003) Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry, 160, pp. 1817-1822.
22. Daumit, G., Crum, R. Guallar, E. et al. (2003) Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics and Whites in the United States. Arch Gen Psychiatry, 60, pp. 121-128.
23. Kelly, DL, Dixon, LB Kreyenbuhl, JA et al. (1994) Clozapine utilization and outcomes by race in a public mental health system: -2000. J Clin Psychiatry; 67, 2006, pp. 1404-1411.
24. Mallinger, JB, Fisher, SG, Brown, T. and Lamberti, JS. (2006) Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv, 57, pp. 133-136.
25. Ministry of Health (2000) The New Zealand Health Strategy, Ministry of Health, Wellington, New Zealand
26. Ajwani, S., Blakely, T., Robson, B., Tobias, M. and Bonne, M. (2003) Decades of disparity: Ethnic mortality trends in New Zealand 1980-1999, Ministry of Health and University of Otago, Wellington, New Zealand
27. Ministry of Health (2004) A portrait of health: Key results of the 2002/ 03 New Zealand Health Survey, Ministry of Health, Wellington, New Zealand
28. Mental Health Commission (1998) Blueprint for mental health services in New Zealand: How things need to be, Mental Health Commission, Wellington, New Zealand
29. Wells, JE, Oakley Browne, MA, Scott, KM, McGee, MA, Baxter, J. and Kokaua, J. (2006) Te Rau Hinengaro: The New Zealand Mental Health Survey: Overview of methods and findings. Aust N Z J Psychiatry, 40, pp. 835-844.
30. Statistics New Zealand (2001) 2001Census: National Summary (2001)-reference report, Statistics New Zealand, Wellington, New Zealand
31. Ministry of Health (2006)
32. Baxter, J., Kokaua, J., Wells, JE, McGee, MA and Oakley Browne, MA. (2006) Ethnic comparisons of the 12 month prevalence of mental disorders and treatment contact in Te Rau Hinengaro: The New Zealand Mental Health Survey. Aust N Z J Psychiatry, 40, pp. 905-913.
33. Te Puni, Kokiri. (1996) Nga ia te oranga hinengaro Maori: Trends in Maori mental health 1984-1993, Te Puni Kokiri, Ministry of Maori Development, Wellington, New Zealand
34. Edmonds, LK, Williams, S. and Walsh, AE. (2000) Trends in Maori mental health in Otago. Aust N Z J Psychiatry, 34, pp. 677-683.
35. Abas, M., Vanderpyl, J., Le Prou, T, Kydd, R., Emery, B. and Foliaki, SA. (2003) Psychiatric hospitalization: Reasons for admission and alternatives to admission in South Auckland, New Zealand. Aust N Z J Psychiatry, 37, pp. 620-625.
36. Gaines, P., Bower, A. Buckingham, B. et al. (2003) New Zealand mental health classification and outcomes study: Final report, Health Research Council of New Zealand, Auckland
37. Wheeler, A., Robinson, E. and Robinson, G. (2005) Admissions to acute psychiatric inpatient services in Auckland, New Zealand: A demographic and diagnostic review. N Z Med J, 118, p. U1752.
38. Ministry of Health (1994) Looking forward: Strategic directions for the Mental Health Services, Ministry of Health, Wellington, New Zealand
39. Ministry of Health (1997) Moving forward: The National Mental Health Plan for more and better services, Ministry of Health, Wellington, New Zealand
40. Ministry of Health (2005) Te Tahuhu-improving mental health 2005-2015: the Second New Zealand Mental Health and Addiction Plan, Ministry of Health, Wellington, New Zealand
41. American Psychiatric Association (2004) Practice guideline for the treatment of patients with schizophrenia, American Psychiatric Association, Washington, DC
42. (2005) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry, 39, pp. 1-30.
43. Chiles, JA, Miller, AL, Crismon, ML, Rush, AJ, Krasnoff, AS and Shon, SS. (1999) The Texas Medication Algorithm Project: Development and implementation of the schizophrenia algorithm. Psychiatr Serv, 50, pp. 69-74.
44. Lehman, AF, Kreyenbuhl, J. Buchanan, RW et al. (2003) The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations. Schizophr Bull; 30, 2004, pp. 193-217.
45. Miller, AL, Hall, CS Buchanan, RW et al. (2004) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry, 65, pp. 500-508.
46. National Collaborating Centre for Mental Health (2002) Schizophrenia: core interventions in the treatment of schizophrenia in primary and secondary care, National Institute for Clinical Excellence, London
47. Lehman, AF and Steinwachs, DM. (1998) Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull, 24, pp. 1-10.
48. Mental Health Commission (1999) New Zealand's National Mental Health Strategy; review of progress 1994-1999, Mental Health Commission, Wellington, New Zealand
49. Walker, RA. (2002) 2001 demographic profile for Waitemata District Health Board: An analysis of 2001 Census
50. Walker, RA. (2002) 2001 demographic profile for Counties Manukau District Health Board: An analysis of 2001 Census
51. Walker, RA. (2002) 2001 demographic profile for Auckland District Health Board: An analysis of 2001 Census
52. Humberstone, V., Wheeler, A. and Lambert, T. (2004) An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry, 38, pp. 240-245.
53. Wheeler, A., Humberstone, V. and Robinson, E. (2008) J Eval Clin Pract
54. Valenstein, M., Copeland, L., Owen, R., Blow, F. and Visnic, S. (2001) Delays in adopting evidence-based dosages of conventional antipsychotics. Psychiatr Serv, 52, pp. 1242-1244.
55. Walkup, JT, McAlpine, DD, Olfson, M., Labay, LE, Boyer, C. and Hansell, S. (2000) Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry, 61, pp. 344-348.
56. Sramek, J., Roy, S., Ahrens, T., Pinanong, P., Cutler, NR and Pi, E. (1991) Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hosp Community Psychiatry, 42, pp. 590-592.
57. Jeste, DV, Lindamer, LA, Evans, J. and Lacro, JP. (1996) Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull, 32, pp. 243-251.
58. Ruiz, P., Varner, RV, Small, DR and Johnson, BA. (1999) Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatr Q, 70, pp. 163-172.
59. Arnold, LM, Strakowski, SM Schwiers, ML et al. (2004) Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res, 66, pp. 169-175.
60. Lin, KM and Finder, E. (1983) Neuroleptic dosage for Asians. Am J Psychiatry, 140, pp. 490-491.
61. Collazo, Y., Tam, R., Sramek, J. and Herrera, J. (1996) Neuroleptic dosing in Hispanic and Asian inpatients with schizophrenia. Mt Sinai J Med, 63, pp. 310-313.
62. Ruiz, S., Chu, P., Sramek, J., Rotavu, E. and Herrera, J. (1996) Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med, 63, pp. 306-309.
63. Sramek, JJ, Sayles, MA and Simpson, GM. (1986) Neuroleptic dosage for Asians: A failure to replicate. Am J Psychiatry, 143, pp. 535-536.
64. Potkin, SG, Shen, Y. Pardes, H. et al. (1984) Haloperidol concentrations elevated in Chinese patients. Psychiatry Res, 12, pp. 167-172.
65. Lin, KM, Poland, RE, Lau, JK and Rubin, RT. (1988) Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol, 8, pp. 195-201.
66. Lin, KM, Poland, RE, Wan, YJ, Smith, MW and Lesser, IM. (1996) The evolving science of pharmacogenetics: Clinical and ethnic perspectives. Psychopharmacol Bull, 32, pp. 205-217.
67. Matsuda, KT, Cho, MC, Lin, KM, Smith, MW, Young, AS and Adams, JA. (1996) Clozapine dosage, serum levels, efficacy, and side-effect profiles: A comparison of Korean-American and Caucasian patients. Psychopharmacol Bull, 32, pp. 253-257.
68. Pinninti, NR, Shaila, B. and Kumar, G. (2003) Racial bias in the prescription atypical of antipsychotics?. Psychiatr Serv, 54, p. 110.
69. Ministry of Health (2002) Te Puawaitanga: Maori mental health national strategic framework, Ministry of Health, Wellington, New Zealand
70. Crawley, L., Pulotu-Endemann, FK and Stanley-Findlay, RTU. (1995) Strategic directions for the mental health services for Pacific Islands people, Ministry of Health, Wellington, New Zealand
71. Sue, S., Fujino, DC, Hu, LT, Takeuchi, DT and Zane, NW. (1991) Community mental health services for ethnic minority groups: A test of the cultural responsiveness hypothesis. J Consult Clin Psychol, 59, pp. 533-540.
72. Stuart, GW, Minas, IH, Klimidis, S. and O'Connell, S. (1996) English language ability and mental health service utilisation: A census. Aust N Z J Psychiatry, 30, pp. 270-277.
73. Ziguras, S., Lambert, TJ, McKenzie, DP and Pennella, J. (1999) The influence of client's ethnicity on psychotropic medication management in community mental health services. Aust N Z J Psychiatry, 33, pp. 882-888.
74. Ziguras, SJ, Klimidis, S., Lambert, TJ and Jackson, AC. (2001) Determinants of anti-psychotic medication compliance in a multicultural population. Community Ment Health J, 37, pp. 273-283.
75. Ajwani, S., Blakely, T., Robson, B., Atkinson, J. and Kiro, C. (2003) Unlocking the numerator-denominator bias III: Adjustment ratios by ethnicity for 1981-1999 mortality data. N Z Med J, 116, p. U456.